<?xml version="1.0" encoding="UTF-8"?>
<list>
  <sentences>
    <s path="[OANC]/data/written_2/technical/biomed/1471-2334-3-9.anc" start="6815" end="6819" sStart="6772" offset="43" sid="r7.1.use.v.0925" wn="1" wnkey="use%2:34:01::" annotator="veweser" text="A plaque assay on CV-1 cells was used to determine the virus titer." />
    <s path="file:/c:/OANC/data/written_2/technical/biomed/1471-2334-3-9.anc" start="6063" end="6068" sStart="null" offset="0" sid="null" wn="1" wnkey="time%1:11:00::" annotator="kaolla" text="Reported EC 50 values are the average and standard deviation of three separate determinations, each replicated three &lt;b&gt;times&lt;/b&gt;." />
    <s path="file:/c:/OANC/data/written_2/technical/biomed/1471-2334-3-9.anc" start="6063" end="6068" sStart="null" offset="0" sid="null" wn="1" wnkey="time%1:11:00::" annotator="carichter" text="Reported EC 50 values are the average and standard deviation of three separate determinations, each replicated three &lt;b&gt;times&lt;/b&gt;." />
    <s path="file:/c:/OANC/data/written_2/technical/biomed/1471-2334-3-9.anc" start="17726" end="17731" sStart="null" offset="0" sid="null" wn="2" wnkey="show%2:31:00::" annotator="carichter" text="In the current study, inhibition of vaccinia infection is not due to photoactivation of the tetrapyrroles, as &lt;b&gt;shown&lt;/b&gt; by two aspects of the experiments." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1471-2334-3-9.anc" start="5891" end="5898" sStart="null" offset="0" sid="null" wn="2147483645" wnkey="null" annotator="cgozo" text="EC 50 values were calculated as response = min + (max-min)/(1+10 [exp(log[drug]-logEC 50 )] using Kaleidagraph (Synergy Software, &lt;b&gt;Reading&lt;/b&gt;, Pennsylvania)." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2334-3-9.anc" start="5316" end="5322" sStart="null" offset="120" sid="r8.number.n.0683" wn="1" wnkey="number%1:07:00::" annotator="brubin" text="The number of plaques was then determined and activity calculated based on the reduction in average number of plaques, in wells where the compound was pre-incubated with the virus, compared to the control wells inoculated with untreated virus." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1471-2334-3-9.anc" start="14269" end="14275" sStart="null" offset="0" sid="null" wn="2147483645" wnkey="null" annotator="cgozo" text="Comparison of the intracellular &lt;b&gt;mature&lt;/b&gt; virion (IMV, third column in Table 1) and extracellular enveloped virion (EEV) forms of the IHD-J strain showed differences in activity of some compounds in blocking infection by the two forms of the virus." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1471-2334-3-9.anc" start="14269" end="14275" sStart="null" offset="0" sid="null" wn="2147483645" wnkey="null" annotator="brubin" text="Comparison of the intracellular &lt;b&gt;mature&lt;/b&gt; virion (IMV, third column in Table 1) and extracellular enveloped virion (EEV) forms of the IHD-J strain showed differences in activity of some compounds in blocking infection by the two forms of the virus." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2334-3-9.anc" start="22975" end="22979" sStart="null" offset="38" sid="r10.high.j.0163" wn="1" wnkey="high%3:00:02::" annotator="cgozo" text="These results, as well as the high therapeutic ratios observed, indicate that these compounds represent attractive candidates as antiviral agents to control poxvirus infection." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2334-3-9.anc" start="15291" end="15295" sStart="null" offset="69" sid="r10.high.j.0760" wn="1" wnkey="high%3:00:02::" annotator="brubin" text="The compounds tested generally inhibited CV-1 cell growth at high concentrations, and 3H-thymidine uptake in HeLa cells by 50% only at concentrations above 20 ?g/mL except for Co(III)TPP(2,6-F2)S (CC 50 &lt; 5 ?g/mL)." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2334-3-9.anc" start="436" end="441" sStart="null" offset="391" sid="r8.1.great.j.0216" wn="1" wnkey="great%5:00:01:large:00" annotator="cgozo" text="Smallpox, while not found in the world's population at present, remains a potential health hazard especially due to the possibility of its use as a bioweapon [ 1 2 3 4 5 ] . There is currently no accepted treatment for smallpox, although a number of agents have been evaluated [ 6 ] . Therefore, new therapeutic or virucidal agents could have great utility in slowing both the progression and spread of the disease in an epidemic situation." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2334-3-9.anc" start="4014" end="4018" sStart="null" offset="61" sid="null" wn="2147483645" wnkey="null" annotator="veweser" text="Compound stock solutions, 5 mg/mL, were diluted 10-fold in DMEM without FBS and mixed with virus particles to five final concentrations: 50, 10, 2, 0.4 and 0.08 ?g/mL." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2334-3-9.anc" start="21067" end="21071" sStart="null" offset="157" sid="r9.fold.v.0039" wn="2147483646" wnkey="null" annotator="veweser" text="The WR strain was 3- to 6-fold less sensitive than IHD-J to several compounds including TAnthPS, CuHPIX, and TPP2FS, but was about 3-fold more sensitive to inhibition by TPP[2,6(OH)2]." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2334-3-9.anc" start="4014" end="4018" sStart="null" offset="61" sid="null" wn="2147483645" wnkey="null" annotator="sophiavv" text="Compound stock solutions, 5 mg/mL, were diluted 10-fold in DMEM without FBS and mixed with virus particles to five final concentrations: 50, 10, 2, 0.4 and 0.08 ?g/mL." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2334-3-9.anc" start="4014" end="4018" sStart="null" offset="61" sid="null" wn="2147483645" wnkey="null" annotator="cgozo" text="Compound stock solutions, 5 mg/mL, were diluted 10-fold in DMEM without FBS and mixed with virus particles to five final concentrations: 50, 10, 2, 0.4 and 0.08 ?g/mL." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2334-3-9.anc" start="20944" end="20948" sStart="null" offset="34" sid="r9.fold.v.0131" wn="2147483645" wnkey="null" annotator="cgozo" text="The WR strain was 3- to 6-fold less sensitive than IHD-J to several compounds including TAnthPS, CuHPIX, and TPP2FS, but was about 3-fold more sensitive to inhibition by TPP[2,6(OH)2]." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2334-3-9.anc" start="21067" end="21071" sStart="null" offset="157" sid="r9.fold.v.0039" wn="2147483646" wnkey="null" annotator="cgozo" text="The WR strain was 3- to 6-fold less sensitive than IHD-J to several compounds including TAnthPS, CuHPIX, and TPP2FS, but was about 3-fold more sensitive to inhibition by TPP[2,6(OH)2]." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2334-3-9.anc" start="4014" end="4018" sStart="null" offset="61" sid="null" wn="2147483645" wnkey="null" annotator="brubin" text="Compound stock solutions, 5 mg/mL, were diluted 10-fold in DMEM without FBS and mixed with virus particles to five final concentrations: 50, 10, 2, 0.4 and 0.08 ?g/mL." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2334-3-9.anc" start="21067" end="21071" sStart="null" offset="157" sid="r9.fold.v.0039" wn="2147483645" wnkey="null" annotator="brubin" text="The WR strain was 3- to 6-fold less sensitive than IHD-J to several compounds including TAnthPS, CuHPIX, and TPP2FS, but was about 3-fold more sensitive to inhibition by TPP[2,6(OH)2]." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2334-3-9.anc" start="4014" end="4018" sStart="null" offset="61" sid="null" wn="2147483645" wnkey="null" annotator="bpassonneau" text="Compound stock solutions, 5 mg/mL, were diluted 10-fold in DMEM without FBS and mixed with virus particles to five final concentrations: 50, 10, 2, 0.4 and 0.08 ?g/mL." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2334-3-9.anc" start="4014" end="4018" sStart="null" offset="61" sid="null" wn="2147483645" wnkey="null" annotator="anfahmy" text="Compound stock solutions, 5 mg/mL, were diluted 10-fold in DMEM without FBS and mixed with virus particles to five final concentrations: 50, 10, 2, 0.4 and 0.08 ?g/mL." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2334-3-9.anc" start="21067" end="21071" sStart="null" offset="157" sid="r9.fold.v.0039" wn="" wnkey="null" annotator="anfahmy" text="The WR strain was 3- to 6-fold less sensitive than IHD-J to several compounds including TAnthPS, CuHPIX, and TPP2FS, but was about 3-fold more sensitive to inhibition by TPP[2,6(OH)2]." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2334-3-9.anc" start="4190" end="4194" sStart="null" offset="39" sid="r11.dark.j.0450" wn="2147483645" wnkey="null" annotator="adelpriore" text="After 1 h incubation (in the dark) the virus-drug mixture was diluted 10-fold in DMEM (without FBS) to 500 ?L and 100 ?L added to each well of confluent CV-1 or BSC-40 cells grown in 24-well plates." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2334-3-9.anc" start="19992" end="19999" sStart="null" offset="436" sid="r9.appear.v.0242" wn="1" wnkey="appear%2:39:00::" annotator="anfahmy" text="Porphyrins and metalloporphyrins have also been shown to have antiviral activity against HIV [ 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 ] . Previous studies indicated that some porphyrins inhibit the interaction between the virus envelope protein and its receptors [ 28 31 32 33 34 35 36 37 38 ] . We have shown also that porphyrins block infection by HIV-1 and that this activity appears to be a result of an interaction with the envelope protein [ 38 ] . In this regard, the compounds that were active in blocking infection by HIV-1 tended to be sulfonated compounds or other negatively charged compounds." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1471-2334-3-9.anc" start="4302" end="4307" sStart="null" offset="0" sid="null" wn="1" wnkey="add%2:30:00::" annotator="veweser" text="After 1 h incubation (in the dark) the virus-drug mixture was diluted 10-fold in DMEM (without FBS) to 500 ?L and 100 ?L &lt;b&gt;added&lt;/b&gt; to each well of confluent CV-1 or BSC-40 cells grown in 24-well plates." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2334-3-9.anc" start="15636" end="15643" sStart="null" offset="150" sid="r11.absence.n.0558" wn="1" wnkey="absence%1:26:00::" annotator="adelpriore" text="The ability of a number of tetrapyrroles to inhibit virus replication was determined in CV-1 cells infected with the WR strain in the absence of compounds." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2334-3-9.anc" start="9048" end="9055" sStart="null" offset="168" sid="r11.absence.n.0162" wn="1" wnkey="absence%1:26:00::" annotator="adelpriore" text="To determine the effect of the compounds on cell proliferation, after 24 h incubation, the cells were washed and further incubated in the absence of the compounds for 1 day, and then a trypan blue assay was done." />
  </sentences>
</list>